Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension

Pulmonary arterial hypertension (PAH) is a life-threatening disease that can be induced by dasatinib, a dual Src and BCR-ABL tyrosine kinase inhibitor that is used to treat chronic myelogenous leukemia (CML). Today, key questions remain regarding the mechanisms involved in the long-term development...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Invest
Main Authors: Guignabert, Christophe, Phan, Carole, Seferian, Andrei, Huertas, Alice, Tu, Ly, Thuillet, Raphaël, Sattler, Caroline, Le Hiress, Morane, Tamura, Yuichi, Jutant, Etienne-Marie, Chaumais, Marie-Camille, Bouchet, Stéphane, Manéglier, Benjamin, Molimard, Mathieu, Rousselot, Philippe, Sitbon, Olivier, Simonneau, Gérald, Montani, David, Humbert, Marc
格式: Artigo
語言:Inglês
出版: American Society for Clinical Investigation 2016
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004960/
https://ncbi.nlm.nih.gov/pubmed/27482885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI86249
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍